V.K. LAZAREVA², R.S. ZAMALEEVA², N.A. CHEREPANOVA¹, E.A. GAPHAROVA², T.P. ZEPHIROVA², M.E. ZHELEZOVA², F.A. PHATTAKHOVA²

¹Volzhsk Central Clinical Hospital, 52 Sovetskaya St., Volzhsk, Russian Federation, 425005

²Kazan State Medical Academy, 51 Bolshaya Krasnaya St., Kazan, Russian Federation, 420015 

Lazareva V.K. — obstetrician-gynecologist, tel. +7-961-379-75-97, e-mail: venera-lazareva@mail.ru

Zamaleeva R.S. — D. Med. Sc., Professor of the Department of Obstetrics and Gynecology № 1, tel. (843) 236-46-41, e-mail: zamaleewa@rambler.ru

Cherepanova N.A. — Cand. Med. Sc., Head of the maternity department, tel. +7-961-376-96-06, e-mail: nat26@list.ru

Gafarova E.A. — Cand. Med. Sc., Assistant of the Department of Obstetrics and Gynecology № 1, tel. (843) 26-46-41, e-mail: lenochkae@list.ru

Zephirova T.P. — D. Med. Sc., Professor of the Department of Obstetrics and Gynecology № 1, tel. +7-987-290-45-99, e-mail: tzefirova@gmail.com

Zhelezova M.E. — Cand. Med. Sc., Associate Professor of the Department of Obstetrics and Gynecology № 1, tel. +7-919-627-13-66, e-mail: gelezovaam@gmail.com

Phattakhova F.A. — Cand. Med. Sc., Associate Professor of the Department of Obstetrics and Gynecology № 1, tel. (843) 236-46-41

There was studied the clinical role of the serum content of regulatory autoantibodies in pregnant women of group of risk, who had no fetus development delay. Complex survey of 181 pregnant women of the risk group is conducted. Along with the standard methods of examination on terms of 11-14 weeks of pregnancy using ELI-TEST solid-phase immunofermental method, the serumal content of some regulatory autoantibodies is defined. There were revealed the features of regulatory autoantibodies in pregnant woman of group of risk of the formation of fetal growth retardation and developed the criteria excluding progress of growth restriction during pregnancy.

Key words: fetus development delay, regulatory autoantibodies, complications of pregnancy, violation of immunoregulation.

REFERENCES

1. Logachev M.F., Shiryaeva T.Yu. Sindrom prenatal’noy zaderzhki rosta i vnutriutrobnoe programmirovanie ego otdalennykh gormonal’no-metabolicheskikh posledstviy [Syndrome prenatal growth retardation and intrauterine programming of its remote hormonal and metabolic consequences]. Avtorskie lektsii po pediatrii. Moscow, 2005. P. 46.
2. Filippov O.S. Platsentarnaya nedostatochnost‘. Klinicheskoe rukovodstvo po effektivnoy pomoshchi [Placental insufficiency. Clinical guidelines for effective aid]. Moscow, 2009. 159 p.
3. Nyukhnin M.A. Klinicheskoe znachenie otsenki soderzhaniya estestvennykh autoantitel dlya optimizatsii taktiki vedeniya beremennykh s otyagoshchennym akusherskim anamnezom: avtoref. dis. … kand. med. nauk [The clinical significance of evaluating the content of natural autoantibodies to optimize the management of pregnant women with a history of obstetric history. Synopsis of dis. PhD med. sci]. Kazan, 2007. 24 p.
4. Cherepanova N.A. Klinicheskoe znachenie urovney regulyatornykh autoantitel dlya otsenki riska razvitiya gestoza: avtoref. dis. … kand. med. nauk [The clinical significance of regulatory levels of autoantibodies to assess the risk of preeclampsia. Synopsis of dis. PhD med. sci]. Kazan, 2008. 24 p.
5. Bukatina S.V. Klinicheskoe znachenie urovney regulyatornykh autoantitel dlya otsenki riska razvitiya krovotecheniya v rodakh i v poslerodovom periode: avtoref. dis. … kand. med. nauk [The clinical significance of regulatory levels of autoantibodies to assess the risk of bleeding during childbirth and the postpartum period. Synopsis of dis. PhD med. sci]. Kazan, 2011. 24 p.
6. Zamaleeva R.S., Lazareva V.K., Cherepanova N.A. The clinical significance of changes in the levels of regulatory autoantibodies in women with ZRP. Tromboz, gemostaz i reologiya, 2013, no. 4, pp. 36-39 (in Russ.).
7. Lazareva V.K., Zamaleeva R.S., Cherepanova N.A. The clinical significance of the determination of regulatory autoantibodies in women with fetal growth retardation. Kazanskiy meditsinskiy zhurnal, 2014, no. 6, pp. 25-28 (in Russ.).
8. Shurshalina A.V., Demura T.A. Morphological and functional reorganization of the endometrium in the “window of implantation”. Akusherstvo i ginekologiya, 2011, vol. 7-2, pp. 9-13 (in Russ.).
9. Zamanskaya T.A. Evseeva Z.P. Evseev A.V. Biochemical screening in the I trimester of pregnancy complications in predicting. Rossiyskiy vestnik akushera-ginekologa, 2009, no. 3, pp. 14-18 (in Russ.).
10. Spencer K., Cowans N.J., Nicolaides K.H. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat. Diagn., 2008, vol. 28, rr. 7-10.
11. Dandona P., Aljada A., O’donnell A. et al. Insulin Is an Anti-inflammatory and Anti-atherosclerotic Hormone. Metab. Syndr. Relat. Disord., 2004, vol. 2, no. 2, pp. 137-142.
12. Y. Xie Q.X., Chen C.Y. et al. Insulin resistance in first-trimester pregnant women with pre-pregnant glucose tolerance and history of recurrent spontaneous abortion. J. Biol. Regul. Homeost. Agents., 2013, vol. 27, no. 1, pp. 225-231.
13. Poletaev A.B., T.S. Budykina, S.G. Morozov. Autoantibodies to insulin-dependent diabetes mellitus and diabetic first type fetopathy. Sakharnyy diabet, 2000, no. 4, pp. 23-28 (in Russ.).